1.4.3.3: D-amino-acid oxidase
This is an abbreviated version!
For detailed information about D-amino-acid oxidase, go to the full flat file.
Word Map on EC 1.4.3.3
-
1.4.3.3
-
d-serine
-
schizophrenia
-
peroxisomal
-
flavin
-
n-methyl-d-aspartate
-
d-alanine
-
catalase
-
fad
-
nmda
-
deamination
-
benzoate
-
flavoenzyme
-
flavoproteins
-
racemase
-
variabilis
-
l-amino
-
neurotransmission
-
d-aspartate
-
gracilis
-
co-agonist
-
rhodotorula
-
cephalosporin
-
glutamatergic
-
urate
-
d-proline
-
d-ala
-
d-ser
-
imino
-
antipsychotic
-
hypofunction
-
d-methionine
-
isoalloxazine
-
acylase
-
fad-containing
-
toruloides
-
rhodosporidium
-
d-glutamate
-
fad-dependent
-
d-cysteine
-
kynurenic
-
sulfurtransferase
-
d-valine
-
synthesis
-
medicine
-
d-leucine
-
cerium
-
7-aminocephalosporanic
-
d-tryptophan
-
d-phenylalanine
-
neuregulin
-
3-mercaptopyruvate
-
sarcosine
-
industry
-
biotechnology
-
analysis
-
diagnostics
-
drug development
-
pharmacology
- 1.4.3.3
- d-serine
-
schizophrenia
- peroxisomal
- flavin
- n-methyl-d-aspartate
- d-alanine
- catalase
- fad
- nmda
-
deamination
- benzoate
-
flavoenzyme
- flavoproteins
- racemase
- variabilis
-
l-amino
-
neurotransmission
- d-aspartate
- gracilis
-
co-agonist
- rhodotorula
- cephalosporin
-
glutamatergic
- urate
- d-proline
- d-ala
- d-ser
-
imino
-
antipsychotic
-
hypofunction
- d-methionine
- isoalloxazine
- acylase
-
fad-containing
- toruloides
- rhodosporidium
- d-glutamate
-
fad-dependent
- d-cysteine
-
kynurenic
- sulfurtransferase
- d-valine
- synthesis
- medicine
- d-leucine
- cerium
-
7-aminocephalosporanic
- d-tryptophan
- d-phenylalanine
- neuregulin
- 3-mercaptopyruvate
- sarcosine
- industry
- biotechnology
- analysis
- diagnostics
- drug development
- pharmacology
Reaction
Synonyms
chDAO, D-AAO, D-amino acid oxidase, D-amino-acid-oxidase, D-aminoacid oxidase, DAAO, DAMOX, DAO, DAO1, DaoE, hDAAO, ophio-amino-acid oxidase, oxidase, D-amino acid, PEG-DAO, pkDAAO, RgDAAO, TvDAAO, TvDAO, LH99
ECTree
Advanced search results
Application
Application on EC 1.4.3.3 - D-amino-acid oxidase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
analysis
biotechnology
diagnostics
-
th enzyme is useful for measurement of D-serine contents in the brain via an implantable D-serine biosensor for in vivo monitoring
drug development
industry
medicine
pharmacology
synthesis
analysis
-
genotyping method development for establishing various pathologic-model animals under the complete care of their intrinsic DAO activity, which are useful for the screening of D-amino acids having physiological activity and/or diagnostic value
analysis
protocols for a variety of direct assays based on the determination of molecular oxygen consumption, reduction of alternative electron acceptors, or alpha-keto acid production, of coupled assays to detect the hydrogen peroxide or the ammonium production, and an indirect assay of the alpha-keto acid production based on a chemical derivatization
analysis
protocols for a variety of direct assays based on the determination of molecular oxygen consumption, reduction of alternative electron acceptors, or alpha-keto acid production, of coupled assays to detect the hydrogen peroxide or the ammonium production, and an indirect assay of the alpha-keto acid production based on a chemical derivatization
analysis
sensitive assay method based on hydrogen peroxide production involving enzyme-coupled colorimetric assay with peroxidase
-
DAAO can be used to synthesize cephalosporin antibiotics
biotechnology
the biotechnological applications of the enzyme range from biocatalysis to convert cephalosporin C into 7-amino cephalosporanic acid to gene therapy for tumor treatment
biotechnology
the biotechnological applications of the enzyme range from biocatalysis to convert cephalosporin C into 7-amino cephalosporanic acid to gene therapy for tumor treatment
biotechnology
the biotechnological applications of the enzyme range from biocatalysis to convert cephalosporin C into 7-amino cephalosporanic acid to gene therapy for tumor treatment
biotechnology
the biotechnological applications of the enzyme range from biocatalysis to convert cephalosporin C into 7-amino cephalosporanic acid to gene therapy for tumor treatment
biotechnology
the biotechnological applications of the enzyme range from biocatalysis to convert cephalosporin C into 7-amino cephalosporanic acid to gene therapy for tumor treatment
biotechnology
the biotechnological applications of the enzyme range from biocatalysis to convert cephalosporin C into 7-amino cephalosporanic acid to gene therapy for tumor treatment
biotechnology
the biotechnological applications of the enzyme range from biocatalysis to convert cephalosporin C into 7-amino cephalosporanic acid to gene therapy for tumor treatment
biotechnology
the enzyme is used as a biocatalyst in cephalosporin C conversion on industrial scale
drug development
-
the enzyme is a potential therapeutic target for schizophrenia treatment
-
the enzyme is used as a biocatalyst for resolving racemic amino acid mixtures, as a tool for biosensing, and as a mechanism of herbicide resistance
industry
-
the enzyme is used as a biocatalyst for resolving racemic amino acid mixtures, as a tool for biosensing, and as a mechanism of herbicide resistance
medicine
-
D-serine availability in the nervous system may be altered in schizophrenia because of increased D-amino acid degradation by DAAO
medicine
-
involvement of DAO (and the interacting gene DAO activator) with a cluster of symptoms involving guilt, anxiety and depression in schizophrenia patients
medicine
-
polyethylene glycol-conjugated D-amino acid oxidase exhibits potent antitumor activity by generating toxic reactive oxygen species, namely oxidation therapy, subsequently shows remarkable antitumor effect on murine sarcoma 180 solid tumor
medicine
potential in vivo applicability of this evolved mutant DAAO, with increased activity at low O2 and D-Ala concentrations and a 10fold lower Km for O2, for tumor therapy
medicine
-
the enzyme inhibition might have an therapeutic effect in schizophrenia treatment
medicine
-
the purified recombinant or native enzyme is used in therapeutic treatment of cancer combined with injection of D-proline. The enzyme is a target in the development of medical treatment for neurodegeneration and cancer
medicine
-
the enzyme is a potential valuable tool for cancer treatments that exploit the production of H2O2
medicine
-
the enzyme is a potential valuable tool for cancer treatments that exploit the production of H2O2
medicine
comprehensive analysis of catalogued DAAO rare variants triggering amyotrophic lateral sclerosis. Certain rare variants disrupt key interactions with the active site and decrease the conformational flexibility of active site loop comprising residues 216-228, which is essential for substrate binding and product release. These variants lost crucial interactions with the cofactor flavin-adenine-dinucleotide, resulting in weaker binding affinity
medicine
in blood serum of individuals with amnestic mild cognitive impairment, mild Alzheimer's disease, moderate to severe Alzheimer's disease, and healthy elderly, the DAO levels increase with the severity of the cognitive deficits. DAO levels are significantly associated with D-glutamate and D-serine levels
medicine
molecular dynamics simulations of wild-type, and all reported amyotrophic lateral sclerosis-associated DAO mutants. The mutations disrupt several key interactions with the active site residues and decrease the conformational flexibility of active site loop comprising 216 to 228 residues, necessary for substrate binding and product release, mainly due to the distortion of critical salt bridge and hydrogen bond interactions compared with wild-type. DAO mutants have a lower binding affinity toward cofactor flavin adenine dinucleotide and substrate iminoserine than the wildtype
medicine
transgenic mice overexpressing mutant R199W show marked abnormal motor features, e.g. kyphosis, associated with a significant loss (19%) of lumbar spinal cord motor neurons, analyzed at 14 months. This effect is greater in females. In transgenic mice expressing mutant R199W and superoxide dismutase SOD1 G93A mutant, overall survival is not affected, but the onset of neurological signs is significantly earlier in female double transgenic animals than their female SOD1 G93A littermates
-
co-administration of the enzyme inhibitor 5-chloro-benzo[d]isoxazol-3-ol significantly enhances the efficacy of D-serine in attenuating prepulse inhibition deficits by administration of dizocilpine, an NMDA receptor antagonist. Therefore, co-administration of D-serine and a DAAO inhibitor has therapeutic potential for the treatment of schizophrenia
pharmacology
diminished DAO activity and elevations in D-serine may serve as an effective therapeutic intervention for the treatment of psychiatric symptoms
-
oxidation of cephalosporin C in the two-step formation of 7-aminocephalosporanic acid
synthesis
-
oxidation of cephalosporin C in the two-step formation of 7-aminocephalosporanic acid
synthesis
-
production of alpha-ketoadipinyl-7-aminocephalosporanic acid
synthesis
-
intracellular production of HDAO under P(GAP), followed by affinity purification and immobilization on oxirane resin, may serve as an effective process for the manufacture of immobilized DAO for industrial application
synthesis
-
immobilization of Trigonopsis variabilis D-amino acid oxidase on solid support is the key to a reasonably stable performance of this enzyme in the industrial process for the conversion of cephalosporin C as well as in other biocatalytic applications
synthesis
-
pig kidney enzyme is used to make L-pipecolic acid from a racemic mixture via D-isomer oxidation
synthesis
the enzyme is used to develop biocatalysts for the production of 7-aminocephalosporanic acid from the natural antibiotic cephalosporin C, and to produce optically active L-methionine from D-amino acid with the yield of 100% in a cascade system of four enzymes, or to produce phenyl pyruvate from D-phenylalanine with the yield of 99%
synthesis
the enzyme is used to produce phenyl pyruvate from D-phenylalanine with the yield of 99%
synthesis
the enzyme might be useful as a biocatalyst for industrial applications and for therapeutic treatments, mechanism of this DAAO variant and on its cytotoxicity towards various mammalian cancer cell lines, overview
synthesis
faster substrate turnover, reduced glutaryl-7-aminocephalosporanic acid inhibition and improved thermostability of the F54Y mutant compared to the wild-type enzyme render it a useful candidate in industrial production of semi-synthetic cephems
synthesis
the soluble expression of is improved in Escherichia coli through N-terminal modification, but the cell biomass is decreased. When a variant carrying an additional glycine in position 3 is fused with three N-terminus histidine residues, the volumetric activity is increased by 3.1 times and the biomass is not significant change compared with the wild type. When the N-terminal disordered region of DAAO (HSQK) is replaced with HHHG, the variant enzyme activity reaches 80.7 U/ml in a 7.5 l fermenter in 24 h
synthesis
use of mutant Y228L/R283G for the deracemization of racemic(RS)-1-phenylethan-1-amine with NaBH4 to produce (1S)-1-phenylethan-1-amine with an enantiomeric excess of 99%
synthesis
use of surface layer (S-layer) protein of Lactobacillus brevis as a self-aggregating protein tag to enable cost-effective separation of human and yeast D-amino acid oxidases expressed in Escherichia coli cells. Human and yeast D-amino acid oxidases fused with S-layer proteins can be easily separated by aggregates at the interface and/or in a few conditions by precipitates to the bottom of the PEG-phosphate aqueous system
synthesis
use of surface layer (S-layer) protein of Lactobacillus brevis as a self-aggregating protein tag to enable cost-effective separation of human and yeast D-amino acid oxidases expressed in Escherichia coli cells. Human and yeast D-amino acid oxidases fused with S-layer proteins can be easily separated by aggregates at the interface and/or in a few conditions by precipitates to the bottom of the PEG-phosphate aqueous system
synthesis
Rhodotorula toruloides ATCC 26217
-
use of surface layer (S-layer) protein of Lactobacillus brevis as a self-aggregating protein tag to enable cost-effective separation of human and yeast D-amino acid oxidases expressed in Escherichia coli cells. Human and yeast D-amino acid oxidases fused with S-layer proteins can be easily separated by aggregates at the interface and/or in a few conditions by precipitates to the bottom of the PEG-phosphate aqueous system
-